WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (NASDAQ: ACUS) issued the following statement today:
“There have been news reports over the weekend and today regarding potential FDA action related to approved and commercially available ultrasound contrast agents. While there has been no official FDA statement, and our company practice is not to comment upon market rumors and reports, especially concerning potential competitors, we believe it is important in light of some of the inquiries we have received today to ensure that investors fully understand Imagify™ (perflubutane polymer microspheres). Imagify is structurally different from commercially available ultrasound contrast agents; it has a different encapsulation material and a different gas.
